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Several studies point to the placenta as the primary cause of pre-eclampsia. Our objective was to identify placental genes that
may contribute to the development of pre-eclampsia. RNA was puriﬁed from tissue biopsies from eleven pre-eclamptic placentas
and eighteen normal controls. Messenger RNA expression from pooled samples was analysed by microarrays. Veriﬁcation of the
expression of selected genes was performed using real-time PCR. A surprisingly low number of genes (21 out of 15,000) were
identiﬁed as diﬀerentially expressed. Among these were genes not previously associated with pre-eclampsia as bradykinin B1
receptor and a 14-3-3 protein, but also genes that have already been connected with pre-eclampsia, for example, inhibin beta
A subunit and leptin. A low number of genes were repeatedly identiﬁed as diﬀerentially expressed, because they may represent
the endpoint of a cascade of events eﬀectuated throughout gestation. They were associated with transcriptional regulation and
vasoregulative pathways, along with a number of hypothetical proteins and gene sequences with unknown functions.
1.Introduction
One of the leading causes of mortality and morbidity
amongst pregnant women and their oﬀspring is pre-
eclampsia (PE), aﬀecting 2%–8% of all pregnancies depend-
ing on the criteria of diagnosis and ethnic population [1].
Pre-eclampsia is deﬁned by hypertension and proteinuria in
the pregnant woman. The symptoms manifest themselves in
the late second or third trimester of pregnancy but there
is most likely a long subclinical course of events before the
debut of symptoms [2]. A rare complication of the con-
dition is eclampsia involving encephalopathia and seizures,
sometimes with a fatal result. For the fetus, pre-eclampsia
commonly leads to intrauterine growth retardation (IUGR),
low birth weight, prematurity, or perinatal death [3]. In
early pregnancy cytotrophoblast cells invade the placental
bed, resulting in a physiological remodelling of the spiral
arteries. During the normal non-pre-eclamptic invasion
process, the trophoblast becomes embedded in the vessel
wall and the muscular and elastic components are disrupted,
transforming the arteries into dilated low resistance vessels.
Thesevesselsareunabletoconstrictinresponsetovasoactive
stimuli thereby ensuring an adequate blood supply to the
placenta and the fetus. In pre-eclampsia, the trophoblastic
invasion is impaired and the spiral arteries retain their
endothelial lining and musculature, compromising blood
ﬂow into the intervillous space and thereby restricting the
blood supply to the placenta and the fetus giving rise to
ischemic hypoxia and oxidative stress [4–6].
Thecauseofpre-eclampsiaisunknown,butitislinkedto
the presence of a placenta, since pre-eclampsia can occur in
molar pregnancies where a placenta, but no fetus, is present
[7]. Also, the only eﬀective treatment of pre-eclampsia is
delivery of the placenta. Studies have shown that some
families are predisposed for development of pre-eclampsia
andithasthereforebeenconcludedthatahereditaryelement
exists [8, 9], most likely to be the result of an interaction
between several diﬀerent genes.
Inanattempttoidentifygenesthatmaybeofimportance
for the pathological and pathophysiological changes seen in
the pre-eclamptic placentas and to identify pre-eclamptic
factors, which may be released into the maternal blood
circulation, we investigated the gene expression in term
placentas from uncomplicated pregnancies and pregnancies2 Journal of Biomedicine and Biotechnology
aﬀected by pre-eclampsia and which may be involved in the
endothelial dysfunction. Throughout this paper, we use the
phrase “term” to designate the end of pregnancy by delivery
at any time during gestation (rather than just full term)
unless otherwise speciﬁed. All the placentas investigated are
from the third trimester. It must therefore be remembered
that the pathways which appear to be regulated in this study
represent the endpoint of what must be presumed to be a
cascade of events eﬀectuated throughout gestation.
2.MaterialsandMethods
2.1. Study Population. This is a case-control-study consisting
of pregnant women with pre-eclampsia and a control
group with an uncomplicated pregnancy. The sole inclusion
criteria used for the women suﬀering pre-eclampsia were a
blood pressure ≥140/90mmHg or a rise in diastolic blood
pressure of ≥30mmHg, proteinuria of ≥300mg/24 hours or
≥300mg/L or ≥1+ by urinary dipstick analysis. Personal or
family history of PE was not recorded. All were self-reported
nonsmokers.TheprojectwasinaccordancewiththeHelsinki
II declaration and approved by the local Ethics Committee.
The women gave their informed consent prior to sampling.
An overview of the clinical data of the included pregnant
women is given in Table 1. The method of delivery diﬀers
between the cases and controls. Most cases relate to vaginal
deliveries and most controls relate to elective Caesarean
sections. This may have inﬂuenced the comparison of genes
implicated in the induction and progression of labour since
these genes may be diﬀerentially expressed due to the process
of labour rather than the pathogenesis of PE. A number
of additional control subjects that were not included in
the array analysis were also analyzed by real-time PCR.
The majority of these controls were multiparous women in
whom, theoretically, a diﬀerent placental gene expression
may exist compared with that of primiparous women.
2.2. Tissue Samples. Placental biopsies were obtained from
the maternal side of term placentas at a maximum of 30
minutes afterdelivery. Biopsies ofapproximately 0.2–0.5cm3
were taken from the center of the cotyledons evenly across
the placenta. Some biopsies were transferred to 10 volumes
of RNAlater solution (Ambion, Austin, Texas) and incubated
at 4◦C over night prior to freezing at −80
◦C. Others were
immediately processedforRNApuriﬁcationbylysisinTrizol
(Invitrogen, Paisley, UK), followed by homogenisation and
centrifugation to remove cellular debris. Hereafter, the lysate
was frozen at −80
◦C. From a subset of the placentas, biopsies
were snap-frozen in liquid nitrogen and stored at −80
◦C.
2.3. Puriﬁcation of RNA from the Tissue Samples. Before
analysis, the RNA was pooled into a total of six groups; three
groups each consisting of equal amounts of RNA from three
pre-eclamptic placentas and three groups each consisting of
equal amounts of RNA from three matched normal controls
(i.e., triplicate experiments a, b, and c with paired cases and
controls, see Table 1). The placental samples were matched
formaternalage,parity,gestationalweekatdelivery,smoking
habits, the gender of the child, and when possible, method
of delivery (but as Table 1 shows this was not possible in all
cases).
RNA was puriﬁed from two biopsies (each of 30mg
cut from the original larger biopsies) from each placenta
using Trizol (Invitrogen) according to the instructions of
the manufacturer. The RNA preparation was subjected to
a clean-up procedure using RNeasy Mini Kit (QIAGEN,
GmbH, Hilden, Germany) according to the instructions
from the manufacturer. RNA concentrations were measured
by spectrophotometer.
2.4. Gene Expression Analysis. T h eg e n ee x p r e s s i o no f
the samples was analysed using GeneChip (HG-U133A,
Aﬀymetrix Inc., Santa Clara, CA, USA) microarrays accord-
ing to the instructions of the manufacturer. In short,
mRNA was reverse transcribed into ﬁrst strand cDNA
using a T7-Oligo(dT) Promoter primer (GenSet/Proligo,
Paris, France), followed by a RNaseH-mediated second-
strand cDNA synthesis. The double-stranded cDNA was
puriﬁed and used as template in an in vitro transcription
(IVT) reaction in the presence of biotin-labelled UTP and
CTP (Enzo Diagnostics) to yield ampliﬁed and biotin-
labelled cRNA (ENZO BioArray HighYield RNA Transcript
Labelling Kit; Aﬀymetrix Inc.). Biotin-labelled cRNA was
cleaned, extracted, and fragmented randomly to approxi-
mately 250bp and hybridized for 16 hours to an Aﬀymetrix
HG-U133A array, containing approximately 22,000 probe
sets representing approximately 15,000 well substantiated
genes. The arrays were washed, stained with phycoerytrin
streptavidin (SAPE) using the Aﬀymetrix Fluidics Station
400 and ﬂuorescent image ﬁles were produced using the
Aﬀymetrix GeneArray scanner 2500.
Evaluation of the results was performed using the DNA-
Chip Analyzer (dChip) programme, a freeware programme
available at http://biosun1.harvard.edu/complab/dchip [10].
The image ﬁles (cel ﬁles) were imported into the software,
and the array ﬁles were normalized using the multiarray
invariant-set normalization method. All arrays in the exper-
iment were normalized to the array with the median overall
brightness, which was selected as the baseline. The invariant-
set normalization is based on probe values belonging to
nondiﬀerentially expressed genes between the array being
normalized and the baseline array (the invariant set). The
invariant set is used to generate a piecewise linear median
curve between the baseline probes and the experiment
probes, which is used at the normalization curve.
M versus A (MVA) plots were constructed after sam-
ple normalization using the Aﬀy package from the R,
BioConductor (http://www.bioconductor.org) to check the
correlation between the replicate samples in each group and
the variation between the normal control group and PE
group, respectively. In the MVA plots the A-axis plots the
average log intensity (log chip1 + log chip2)/2 and the M-
axis plots the log of ratio (chip1/chip2). A matrix of MVA
plots was constructed for Control, Pre-eclampsia, and both
samplegroups,wheretheMVAplotsareshowedintheupper
triangle and the IQR (interquartile range) of the Ms andJournal of Biomedicine and Biotechnology 3
Table 1: Clinical data on the included women and deliveries.
Pre-eclampsia Control
Chip
pool Age Para Weeks of
gestation
Sex of
child
Smoking Delivery Co-morbidities Chip
pool
Age Para Weeks of
gestation
Sex of
child
Smoking Delivery
A2 6I 39 M NI L A 27 I 39 M NE S
A2 9I 37 F NI L A 35 I 38 F NE S
A 29 I 39 M NI L A 35 I 38 M NE S
B3 2 I 33 M NE S B 33 I 35 M NI L + S
B2 5 I 39 F NI L ∗ B 26 I 39 F NE S
B2 6 I 40 M NI L B 28 I 39 M NE S
C2 4I 38 F N V unc C 32 I 39 F N V unc
C2 9 II 37 F N V unc C 30 II 39 F NE S
C3 5I 37 M N V unc C 33 I 38 M NE S
—2 9I 32 M NA S ∗∗
—2 4I 36 M NA S
— 27 II 38 M NE S
— 34 V 38 M NE S
— 29 II 39 M NE S
— 38 IV 38 F NE S
— 36 III 37 M NE S
— 25 I 39 F NE S
— 35 II 38 M NE S
— 31 II 38 M NE S
— 33 II 38 F NA S
Italics mean no real-time PCR experiments performed. Paired pre-eclamptics and controls for microarray analysis are listed on the same line in the table. IL =
induction of labour, ES = elective sectio, AS = a c u t es e c t i o n ,Vu n c= uncomplicated vaginal delivery Co-morbidities: ∗abortus imminens, ∗∗possible HELLP.
the Median of the As are displayed in the lower triangle. A
model-based expression index was calculated using perfect
match signals only and comparisons between sample groups
were performed. For all comparison analyses, the following
parameters were used: Minimum fold change of 1.2 fold,
minimum absolute change in signal intensity of 50 units and
a P-value for the change in signal intensity of.05 or less.
The dChip software calculates the upper and lower bounds
of a 90 percent conﬁdence interval for the fold change. We
have ﬁltered our results by the lower bound fold change,
which is the more conservative estimate of the fold change.
The triplicate pairs of samples were analyzed on six separate
arrays. For analysis, the control arrays were grouped together
and their mean signals were compared with the mean signals
of the case arrays. From the resulting list of genes generated
by dChip, we chose a number of genes to verify by real-time
PCR.
2.5. Veriﬁcation of Results from the Gene Expression Anal-
ysis by Real-Time PCR. A number of genes found to be
diﬀerentially expressed between case and control placentas
were examined by real-time PCR using a LightCycler instru-
ment (Roche). The genes we focused on were ﬁbulin 1A,
inhibin, leptin, and tyrosine 3-monooxygenase/tryptophan
5-monooxygenase activation protein. Templates for the
veriﬁcation were the RNA preparations from individual
placentas. Nine RNA preparations originated from pre-
eclamptic placentas and twelve preparations originated from
control placentas. A minimum of two diﬀerent biopsies for
each placenta were included in the preparation. From the
RNA preparations, cDNA was synthesized using Superscript
II RNase H- Reverse Transcriptase (Invitrogen, CA, USA)
according to the instructions of the manufacturer. Equal
amounts of total RNA (1.7μg) were used for all reverse
transcription reactions. All cDNA templates were diluted
25× in water before analysis. All primers were used in a ﬁnal
concentration of 0.5μM each and the MgCl2 concentration
was 2mM for all reactions. Primers and PCR conditions for
each gene are listed in Table 2. A varying number of touch-
down cycles were performed before the PCR to improve
speciﬁcity. The annealing temperature and the number of
cycles for which it was used are listed in Table 2.A l lr e a c t i o n s
were carried out in a total volume of 16μL, using 1.6μLo f
diluted template and 1.6μL LightCycler FastStart Reaction
Mix SYBR Green I (Roche) prepared according to the manu-
facturer’s instructions. Standard curves were performed for
each run to ensure the comparability of the samples. For
generationofastandardcurveofsampleﬂuorescenceagainst
relative template concentration, we used a pool of equal
amounts of all 22 individual cDNA preparations as template.
Undiluted template pool and dilutions of 25×,5 0 ×,a n d
100× were used to generate the standard curve. All the indi-
vidualresultswereevaluatedagainstthiscurve.Furthermore,
GAPDH expression was determined for all samples and
used for normalization before statistical analysis was carried
out.4 Journal of Biomedicine and Biotechnology
Table 2: Primers and PCR conditions.
Gene target Forward primer 5 -3  Reverse primer 5 -3  TD
a aT D
a bT D
a cT D
a dP C R
b
◦C/c
◦C/c
◦C/c
◦C/c
◦C/c
Fibulin 1A aagttggcaggagtggagac cccccataggtgaatcacag 58/25 7 /25 6 /2— 5 5 /35
sFLT-3 taagcacaccacgcccagtc aagaccgcttgccagctacg 69/26 8 /26 7 /2— 6 6 /30
Inhibin gcttcatgtgggcaaagtcg ccccctttaagcccacttcc 64/26 2 / 60/ 59/25 8 /30
Leptin gtccaagctgtgcccatcc cccaggctgtccaaggtctc 64/26 2 / 60/ 59/25 8 /30
(a)Touchdown cycle, annealing temperature/number of cycles.
(b)PCR, annealing temperature/number of cycles.
Con-a1
Median: 0.00577
IQR: 0.376
Median: −0.00945
IQR: 0.522
Median: −0.0117
IQR: 0.355
Median: −0.000284
IQR: 0.344
Median: −0.0124
IQR: 0.461
Median: −0.0121
IQR: 0.501
Median: −0.00473
IQR: 0.407
Median: −0.0158
IQR: 0.418
Median: −0.0122
IQR: 0.541
Con-b1
Median: 0.00818
IQR: 0.268
Median: 0.0086
IQR: 0.444
Median: 0.00843
IQR: 0.441
Con-c1
Median: −0.00488
IQR: 0.421
Median: 0.0108
IQR: 0.294
PE-a1
Median: −0.00691
IQR: 0.392
PE-b1
PE-c1
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Figure 1: The interquartile range (IQR) values for the MVA plots show that the variation between the arrays within each group (case versus
case or control versus control) is in the same range as the variation between the groups (case versus control). This indicates a high similarity
between the case and control groups which is also apparent by the relatively low number of diﬀerentially expressed genes identiﬁed.Journal of Biomedicine and Biotechnology 5
2.6. Statistical Analysis. The results generated from the real-
time PCR experiments were compared using Mann-Whitney
test.
3. Results
3.1. Microarray Data. A total of 21 genes were found to
be diﬀerentially expressed between the arrays by dChip
analysis, of these 9 were downregulated and 12 upregulated.
T h eg e n e sa r el i s t e di nTable 3.Am a t r i xo fMv e r s u sA
(MVA) plots was constructed for Controls, Pre-eclampsia
and both sample groups (Figure 1). The interquartile range
(IQR) values for the MVA plots showed that the variation
between the arrays within each group (case versus case or
controlversuscontrol)wasin thesame rangeasthe variation
between the groups (case versus control). This indicated a
high similarity between the case and control groups, which
is also apparent by the relatively low number of diﬀerentially
expressed genes identiﬁed.
The genes chosen for real-time PCR veriﬁcation were
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase
activation protein and ﬁbulin 1A on the basis of their fold
change and their novelty in relation to the pathogenesis of
PE. Inhibin and leptin have previously been associated with
PE and were included as a veriﬁcation of the PCR setup.
3.2. qRT-PCR Data. The relative expression levels calcu-
lated from the real-time PCR experiments are depicted in
Figure 2.Theregulationofﬁbulinbetweencasesandcontrols
observed on the arrays was not conﬁrmed. The array analysis
result was shown to have been inﬂuenced by a single sample
expressing large amount of ﬁbulin mRNA and the diﬀerence
in expression observed by real-time PCR did not reach
statistical signiﬁcance (P = .619; FC 1.46). The diﬀerential
expression indicated by the array analysis for leptin was ver-
iﬁed (P = .012; FC 3.41). The diﬀerence in expression levels
for inhibin and tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein did not reach signiﬁcance
(P = .500, FC 1.13; P = .166, FC − 1.27). The expression
patterns for the genes examined by real-time PCR thus in
general conﬁrm the trends observed by microarray analysis.
4. Discussion
The most interesting feature of this study is the similarity
between the arrays and the potential signiﬁcance of the
expression of 21 out of possible 15,000 genes. In hindsight
that may not be very surprising. It is generally agreed that
pre-eclampsia has a long subclinical course before the onset
of symptoms and the main part of the causative placental
molecular events that lead to the development of PE is
temporary and may not be apparent at term. Also, tissues
other than the placenta, such as the maternal vascular
endothelium, may play a role in the pathogenesis of PE. This
study includes cases of both late (n = 9) and early onset
PE (n = 2) (cut-oﬀ 34 weeks of gestation). The pooled
samples may mask any diﬀerences between the pathogenesis
of late and early onset PE, but should on the other hand
ensure that any gene expression diﬀerences detected is more
likely a representative of the disease as a whole. We have also
includedtruebiologicalreplicatesinthecurrentstudydesign
bypoolingsamplesfromothercompletelyindependentcases
and controls; this is in contrast to several other published
studiesregardinggeneexpressioninpre-eclampticplacentas,
and should be a strength of the current study.
In the following, descriptions of the transcripts found
to be diﬀerentially expressed by microarray analysis and/or
further analysis are given and their relevance in relation
to the pre-eclamptic syndrome is discussed. The sequences
have been grouped in sections according to their possible
inﬂuence on certain characteristics of pre-eclampsia: inade-
quate placentation, oxidative stress, inﬂammatory response,
hypertension, and metabolism. Throughout the discussion,
one should bear in mind that the results from this study
rests on mRNA analysis only and that the mRNA expression
proﬁleofanybiologicalsystemmaynotnecessarilyreﬂectthe
protein proﬁle. Finally, a brief evaluation of the microarray
experiment is given, followed by a general discussion, and a
conclusion.
4.1. Gene Descriptions and Regulations
4.1.1. Inadequate Placentation. A complex of diﬀerent thy-
roid hormone receptor-associated proteins (TRAPs) play
a role as coactivators for thyroid hormone dependent
transcriptional activation [11]. The placenta may be a
thyroid hormone dependent tissue. Stimulation by thyroid
hormones of trophoblast endocrine function resulting in
enhanced production of human placental lactogen and
human chorionic gonadotropin has been reported [12].
It has also been shown that L-triiodothyronine enhances
the production of epidermal growth factor, a potent tro-
phoblast mitogen [13]. Thyroid hormones may thus have
an important role in villous development and placentation,
in part mediated by the interaction between endocrine and
autocrine factors [14]. We found a 240kDa subunit (TRAP
240) expression decreased by 1.32 fold, which may indicate
an impaired thyroid hormone signalling perhaps involved in
the inadequate placentation observed in PE.
4.1.2.OxidativeStress. Theselenoproteinthioredoxinreduc-
tase (TrxR1) is a cytosolic antioxidant enzyme known to
reduce many compounds in addition to thioredoxin, its
principle protein substrate. It functions to eliminate reactive
oxygen species (ROS) and regenerate oxidatively damaged
proteins. Some have found that the levels of oxireductases,
thioredoxin reductase included, were increased approxi-
mately 2- to 3-fold in pre-eclamptic placentas compared
to normal placentas and it was speculated that this might
be an adaptive response to the oxidative stress observed
in PE [15]. The same group of investigators has also
shown that oxidative stress does indeed induce thioredoxin
reductase expression in the trophoblast [16]. However, we
found thioredoxin reductase to be downregulated (1.57
fold) in the pre-eclamptic placentas compared with the
normal controls. Failure to increase thioredoxin reductase
may further promote a condition of oxidative stress.6 Journal of Biomedicine and Biotechnology
Table 3: Regulation of genes in pre-eclamptic placentas compared to controls.
Accession1 Gene of interest Fold change P-value
Antioxidant enzymes
NM 003330.1 thioredoxin reductase 1 −1.57 .025
Eicosanoid metabolism
U63296.1 hydroxyprostaglandin dehydrogenase 15-(NAD+), 1.48 .027
BC005939.1 prostaglandin D2 synthase 21kDa (brain) −1.51 .031
Energy metabolism
AI761561 hexokinase 2 1.59 .045
NM 000230.1 leptin 2.94 .025
AA502643 tyrosine 3-monooxygenase/tryptophan
5-monooxygenase activation protein e
−1.65 .005
Inhibin-activin system
NM 002192.1 inhibin, beta A subunit (activin A, activin AB alpha
polypeptide)
2.06 .007
Matrix proteins
NM 000494.1 collagen, type XVII, alpha 1 1.50 .039
NM 006487.1 ﬁbulin 1A −2.49 .009
Transcription factors
AA972711 zinc ﬁnger protein 292 −1.37 .024
NM 005121.1 thyroid hormone receptor-associated protein, 240kDa
subunit
−1.32 .012
Vascular factors
NM 000710.1 bradykinin B1 receptor −1.44 .024
NM 013332.1 hypoxia-inducible protein 2 1.61 .029
Miscellaneous
AI206718 ESTs, Weakly similar to zinc ﬁnger protein 339 1.52 .024
AF052169.1 hypothetical protein BC013764 −1.46 .033
AF007149.1 hypothetical protein LOC257407 −1.40 .035
AK025495.1 KIAA0790 protein 1.56 .041
AK027231.1 KIAA1102 protein 1.54 .003
AB033025.1 KIAA1199 protein 1.59 .040
NM 004844.1 SH3-domain binding protein 5 (BTK-associated),
(signal transduction)
1.58 .030
AF016535.1 ATP-binding cassette, sub-family B (MDR/TAP),
member 1, (transporter activity)
1.45 .037
1Genbank accession number.
4.1.3. Inﬂammatory Response. Tyrosine 3-monooxygenase/
tryptophan 5-monooxygenase activation protein, epsilon
variant, is a so-called 14-3-3 protein. Interestingly, 14-3-
3 proteins have also been found to exhibit antiapoptotic
characteristics [17]. A decrease of 14-3-3, as identiﬁed by
microarray analysis and real-time PCR, could therefore
increase the occurrence of apoptosis in placental cells and
therebyalsoincreasethelevelofplacentalcellulardebrisshed
into the maternal blood circulation. Syncytiotrophoblast
microvillous membrane (STBM) fragments have been found
at higher concentrations in the circulation of pre-eclamptic
women compared to women with uncomplicated pregnan-
cies [18]. It has been proposed that STBMs contribute to the
vascular endothelial dysfunction of pre-eclamptic women.
4.1.4. Inhibin, Beta A Subunit. Activins and inhibins are
growth and diﬀerentiation factors belonging to the trans-
forming growth factor-beta superfamily. The activins are
dimeric proteins consisting of two inhibin beta subunits
(beta A homodimer or beta A beta B heterodimer). Either
of the beta subunits in combination with an inhibin alpha
subunit yield the protein inhibin, which has functions quite
opposite of those of activin in that inhibin will inhibit the
actions of activins. It has been shown that women with
pre-eclampsia have increased serum levels of inhibin A
and activin A [19]. Inhibin mRNA levels in pre-eclamptic
placentas are elevated compared to normal controls [20]
and activin A mRNA and protein are also increased [21,
22] suggesting that placental expression may contributeJournal of Biomedicine and Biotechnology 7
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Figure 2: The expression patterns of the sequences as determined by real-time PCR. White bars represent pre-eclampsia cases; grey
bars represent controls. Each bar represents the mean (+SEM) relative expression of the individual samples in the experiment. P-
values for comparisons between cases and controls were: Fibulin (.619; FC 1.46), leptin (.012; FC 3.41), inhibin (.500; FC 1.13), tyr 3-
monooxygenase/tryp 5-monooxygenase activation protein ε (P = .166; FC − 1.27); Mann-Whitney test. (Pre-eclampsia cases: n = 9,
controls: n = 12; one control placenta was found to have a cDNA yield which was signiﬁcantly lower than the other samples and it was
therefore excluded from the subsequent analyses).
to the rise in serum concentrations, possibly more so
for activin A than for inhibin A [22]. Activin A is also
involved in inﬂammatory responses, though it seems to be
dependent on dose whether the eﬀe c ti te x e r t si sa n t i -o r
proinﬂammatory [23]. Thus activin A may play a role in the
maternal inﬂammatory response observed in pre-eclampsia.
Microarray analysis indicated a 2.06-fold upregulation of
inhibin beta A subunit, which was conﬁrmed by real-time
PCR (1.9-fold up-regulation). There is an increase of activin
A levels in pre-eclampsia. Inhibin beta A subunit is part
of activin A and may therefore directly contribute to the
increased levels observed.
4.1.5. Hypertension. The eicosanoids such as prostaglandin
and thromboxane are important mediators of blood vessel
contractility and blood pressure regulation. We found two
enzymes involved in the eicosanoid metabolism to be
regulated between the pre-eclamptic placentas and the nor-
mal controls—hydroxyprostaglandin dehydrogenase 15 and
prostaglandin D2 synthase. Hydroxyprostaglandin dehydro-
genase 15 (15-PGDH, type I) is the main enzyme converting
prostaglandins E2 and F2 to their biologically inactive 15-
keto derivatives. Prostaglandin acts as a vasodilator. One
study has found a twofold reduction of PGDH mRNA levels
in placental tissue of patients with pre-eclampsia, compared
with matched controls [24]. Others have found an increase
in the activity of PGHD in pre-eclamptic placentas [25].
We found an upregulation (1.48-fold) of PGDH in the pre-
eclampticplacentas.PGDHisinvolvedinparturitionandthe
expression is therefore dependent of the mode of delivery.
During normal pregnancy at full term, PGDH transcription
and activity in the chorio-decidua is reduced [26], allowing
prostaglandins to reach the myometrium and to increase
myometrial contractility. The placental expression does not
seem to be aﬀected [26] .I no u rs t u d y ,am a j o r i t yo ft h e
women in the PE group delivered vaginally, while almost
all of the controls underwent elective Caesarean sections.
Even taking this bias into account, the eﬀect of parturition
in the PE group should not be an increase of placental
PGDH and it is therefore possible that PGDH plays a role
in the pathogenesis of PE. Increased levels of PGDH would
lead to decreased levels of biologically active vasodilatory8 Journal of Biomedicine and Biotechnology
prostaglandins, which might contribute to a hypertensive
state. Since results from diﬀerent studies on the placental
PGDH expression in PE are conﬂicting, further investigation
is necessary.
Glutathione- (GSH-) independent PGD2 synthase cat-
alyzes the conversion of prostaglandin H2 (PGH2) to PGD2
in the presence of various sulfhydryl compounds. One study
showed that PGD2 synthase concentration in amniotic ﬂuid
is decreased in abnormal pregnancies [27]. It has been
suggestedthat PGD2might contribute to the maintenance of
pregnancy by controlling the Th1/Th2 balance and antigen
presentation by dendritic cells through a dual receptor
system [28]. Prostaglandins are vasodilators and a down-
regulation of prostaglandin D2 synthase as identiﬁed by
our microarray analysis (1.51-fold) may contribute to the
hypertensive state of PE. Its aberrant expression may also
inﬂuence the reversal of the Th1/Th2 balance from that of
normal pregnancies to that of pre-eclampsia.
Hypoxia-inducible protein 2 (hypoxia-inducible factor 2
alpha (HIF2A)) is a transcription factor, which is activated
by hypoxic conditions. It is capable of speciﬁcally activating
the transcription of the endothelial tyrosine kinase gene
Tie-2 involved in angiogenesis [29]. Knock-out experiments
in mice have shown that HIF2A also plays a role in
the up-regulation of expression of the vasoconstrictors
catecholamine and endothelin-1 [30, 31]. We found HIF2A
mRNA expression up-regulated by 1.61-fold in PE. Others
have previously found HIF2A protein, but not mRNA,
expression upregulated in pre-eclamptic placentas [32]. The
same investigators also found that villous explants from PE
placentas fail to adequately downregulate hypoxia-induced
HIF protein expression upon oxygenation [33].
Bradykinin B1 receptor is an inducible receptor,
expressed during inﬂammatory conditions under the inﬂu-
ence of cytokines. It mediates a vasorelaxing eﬀect by induc-
ing nitric oxide release. Bradykinin is a powerful angiogenic
stimulus in vivo and in vitro. We found the expression of
bradykininreceptorB1inpre-eclampticplacentastobe1.44-
fold less than that in the normal controls, indicating that it
might be involved in the development of hypertension and
insuﬃcient placental vascular growth associated with PE.
The leptin hormone is produced by adipose tissue and
by the placenta during pregnancy [34]. In nonpregnant
humans, leptin negatively regulates food intake and body
weight via its receptor in the hypothalamus [34]. Leptin
has also been shown to correlate with plasma insulin levels
and an association between insulin resistance and resistance
to leptin has been suggested [35]. In normal pregnancy,
leptin levels increase, particularly in the second trimester,
and decline postpartum [36]. Several studies have found
leptin even further upregulated in pre-eclamptic pregnancies
(see review by Poston [37]) while others have not been
able to prove this association [38, 39] and one study has
foundthatleptinlevelsweredecreasedinpre-eclampsia[40].
Some have suggested that upregulation of leptin in pre-
eclampsia may cause maternal leptin resistance, which may
be a component of insulin resistance, predisposing the onset
of endothelial dysfunction [35]. An increase in maternal
leptin levels may cause a rise in blood pressure through
stimulation of sympathic activity, or it may have beneﬁcial
consequences, such as stimulation of fetal growth. It has
been proposed that leptin controls the functional integrity
of the feto-placental unit thereby maintaining pregnancy by
virtue of its immunoregulatory property via T lymphocytes
or proto-oncogenes [41]. We found leptin to be upregulated
in the placenta in pre-eclamptic pregnancies. Others have
also found leptin levels upregulated by microarray analysis
[42, 43]. Our microarray analysis indicated an upregulation
of 3.2-fold. Real-time PCR analysis yielded an up-regulation
of approximately 32-fold. It shall be noted that such large
diﬀerences in fold-change between microarray and corre-
sponding PCR experiments are often observed.
4.1.6. Miscellaneous. A number of hypothetical proteins and
gene sequences with unknown functions were also found
to have expression levels that were markedly diﬀerent in
the pre-eclamptic group compared to the control group.
Further investigation is needed before their relevance to the
development of PE can be elucidated.
4.2. Microarray Analysis. The real-time PCR experiments in
general exhibited the same trends of regulation that were
evident from the array analyses. The risk of single samples
biasing the overall results will always be a downside to anal-
ysis of pooled materials on microarrays and the importance
of additional experiments to conﬁrm the microarray results
must be emphasized. Microarray studies of placental gene
expression in pre-eclamptic placentas versus a control group
data analysis with a speciﬁed set of parameters showed 59
genes [42], 96 genes [44], 137 genes [45], and 36 genes
[45, 46] signiﬁcantly diﬀerentially regulated between the
two groups. Three of the genes exhibiting up-regulation are
also present among the up-regulated genes identiﬁed in our
study, namely, collagen XVII alpha 1, leptin, and inhibin
beta A subunit. When comparing results from diﬀerent case-
control gene expression studies—microarrays, proteomic
studies, or even gene-speciﬁc studies, several aspects must
be taken into consideration. Firstly, diﬀerences in detection
limitsandanalysisparametersmayexist.Secondly,thedesign
of the case and control groups will inﬂuence the results.
The clinical characteristics, such as mean gestational age and
parity of the included patients, will be of importance as well
as the cellular composition of the placental samples. The
mean gestational age of our study is higher (37.9 weeks for
the samples studied on the microarrays) than that of the
study of Reimer et al. [42] (mean gestational age 30.7 weeks)
andunlikeReimeretal.wedidnotremovematernaldecidual
tissuefromtheplacentalbiopsies.Ourcontrolgroupconsists
of women that have had uncomplicated pregnancies until
delivery, the main part of which delivered by elective
Caesarean section due to indications unrelated to the course
of pregnancy. Finally, our study utilized the U133A chip,
which represents sequences from ∼15,000 genes.
T h ep r e v i o u ss t u d i e so fg e n ee x p r e s s i o ni np r e - e c l a m p t i c
andcontrolplacentalsampleshaverevealeddiﬀerencesinthe
expression of immunologic factors. This was also observed
in the microarray study by Reimer et al. [42]. For example,Journal of Biomedicine and Biotechnology 9
Human Leukocyte Antigen-G (HLA-G) has been found to
be diﬀerentially expressed in several studies. By relaxing the
parameters of our data analysis (speciﬁcally by ﬁltering the
genes according to the upper bound value of the conﬁdence
interval for the fold changes), immunological genes such as
T-cellreceptorgamma-delta,killercellimmunoglobulin-like
receptors, and HLA-G were also found to exhibit diﬀerences
in expression between pre-eclampsia pools and controls. In
some of the previously published studies, gestational ages
were also shorter and other genes may be important in the
pathogenesis of pre-eclampsia at these stages of pregnancy.
So even though this study did not identify immunological
factors as being diﬀerentially expressed, an immunological
component in the pathogenesis of pre-eclampsia cannot be
excluded for the ﬁrst and second trimesters of pregnancy.
In conclusion, microarray analysis of the gene expression
in pre-eclamptic placentas compared to that of normal
controls indicated the regulation of a surprisingly small
number of genes. However, the fact that others have
found some of these genes regulated in connection with
pre-eclampsia strengthens the credibility of the results of
this study. Leptin and inhibin beta A subunit were both
found to be up-regulated, which was conﬁrmed by real-
time PCR and which is consistent with the ﬁndings in
other studies. These and other secreted factors may be of
importance to the development of the maternal vascular
endothelial dysfunction observed in pre-eclampsia. Apart
from placental secreted proteins, other placental factors,
perhaps including 14-3-3 proteins, working to increase the
shedding of syncytiotrophoblast microvillous membranes
(STBMs) into the maternal circulation may also contribute
to this, since STBMs are found at higher concentration
in the circulation of pre-eclamptic women compared to
women with uncomplicated pregnancies [18]. Genes pre-
viously found to be connected with PE, such as thiore-
doxin reductase, hydroxyprostaglandin dehydrogenase, and
hypoxia-inducible protein 2 alpha, were also identiﬁed by
our array analysis. Furthermore, the microarray analysis
yielded diﬀerential expression patterns between cases and
controls for a number of novel factors not previously
connected with PE, for example, prostaglandin D2 synthase
and TRAP240. Surprisingly, no immunological factors were
identiﬁed, but this may be because the pathways that we
ﬁnd regulated in this study represent the endpoint of what
must be presumed to be a cascade of events eﬀectuated
throughout gestation. Early immune maladaptation may
contribute to the shallow trophoblast invasion of the spiral
arteries and the lack of spiral artery conversion into high-
capacitance vessels observed in PE. This leads to a reduced
placental perfusion and therefore a reduced nutrient supply
and the generation of a hypoxic placental environment.
Some of the genes identiﬁed in this study are hypoxia
inducible transcription factors. Other genes implicated in
gene transcription, such as additional transcription factors
and proteins involved in growth factors signalling, were also
found to be regulated. We hypothesize that factors induced
by hypoxia or a reduced nutrient supply may contribute
to an alteration of the regulation of gene expression in the
pre-eclamptic placenta. Thus, some of the genes previously
reported to be diﬀerentially expressed in pre-eclampsia may
be so due to an aberrant regulation of expression rather
than dysfunctional genes themselves. This, of course, does
not mean that certain polymorphisms or mutations may
not predispose to the development of PE and indeed several
studies have shown associations between PE and genetic
polymorphisms. These observations may partly explain the
complexity of the disease and the vast number of genes
[8] that have been implicated in the pathogenesis of pre-
eclampsia up till now.
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